112 reports of this reaction
0.7% of all LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN reports
#18 most reported adverse reaction
PROSTATE CANCER is the #18 most commonly reported adverse reaction for LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, manufactured by Novartis Pharmaceuticals Corporation. There are 112 FDA adverse event reports linking LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN to PROSTATE CANCER. This represents approximately 0.7% of all 14,999 adverse event reports for this drug.
Patients taking LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN who experience prostate cancer should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PROSTATE CANCER is a less commonly reported adverse event for LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, but still significant enough to appear in the safety profile.
In addition to prostate cancer, the following adverse reactions have been reported for LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN:
The following drugs have also been linked to prostate cancer in FDA adverse event reports:
PROSTATE CANCER has been reported as an adverse event in 112 FDA reports for LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN. This does not prove causation, but indicates an association observed in post-market surveillance data.
PROSTATE CANCER accounts for approximately 0.7% of all adverse event reports for LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, making it a notable side effect.
If you experience prostate cancer while taking LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.